EuropaBio, the European Association for Bioindustries, is proud to continue our platform for engaging patient and industry alike on pertinent healthcare debates: the Patient Bio-Forum. In this edition the focus will be on the impact of European Reference Networks (ERNs).
With an aim to facilitate discussion between patients and medical professionals across the EU, ERNs tackle rare disease head on. Creating a pooled, virtually accessible network of experts, ERNs demonstrate the power of collaboration in diagnosis complex and rare diseases. With the first ERNs having started in 2017, we anticipate a periodic evaluation during 2022/23. Similarly, this year the Commission have undertaken an evaluation of the Cross-border Healthcare Directive which establishes the legal basis of ERNs.
Against a backdrop of societal change, the EuropaBio Patient Bio-Forum convenes this October with a panel of experts representing patient, industry, EU and Member State perspectives on the challenges, achievements and opportunities the ERNs present.
AGENDA
Welcome and introduction (5 mins)
Panel Discussion (45 mins)
Biobreak/Slido Poll (5 mins)
Moderated Q&A (35 mins)
Closing remarks
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Algal Omage-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of algal omega-3 used.